Altimmune ALT
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 83rd percentile, 5-year average -4.1x
Near the bottom of its 5-year range · 4th percentile, 5-year average 2.4x
#1104 of 5311 stocks by PB (1 = cheapest)
Above its usual level · 69th percentile, 5-year average 6,798.6x
#5135 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 0.84 | – | 2.42 | 4% (cheaper than usual) | #1104 of 5311 (1 = cheapest) |
| PE | -2.68 | -3.67 | -4.11 | 83% (pricier than usual) | – |
| PS | 12,800.52 | – | 6,798.55 | 69% (pricier than usual) | #5135 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ALT.
Sign in to join the discussion.